August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Mahadi Baig: New Study Highlights Benefits of Subcutaneous Amivantamab with Lazertinib
Jul 18, 2025, 13:46

Mahadi Baig: New Study Highlights Benefits of Subcutaneous Amivantamab with Lazertinib

Mahadi Baig, Vice President, Head of Solid Tumors, US Medical Affairs at Johnson and Johnson, posted on LinkedIn about recent article by Mariam Alexander et al., published on European Journal of Cancer.

“Excited to share our newest publication demonstrating subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, is a preferred option for patients receiving amivantamab-lazertinib.

Title: Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study

Authors: Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I. Spira, Byoung Chul Cho, Sun Min Lim, Yuichiro Ohe, Adnan Nagrial, Jiunn Liang Tan, Vanina Wainsztein, Elisa Ramos, Maria del Rosario Garcia Campelo, Hiroaki Akamatsu, Danny Nguyen, Alexis B. Cortot, Alona Zer, Dilek Erdem, Rachel E. Sanborn, Till-Oliver Emde, Natasha B. Leighl

Read The Full Article at European Journal of Cancer.

Mahadi Baig: New Study Highlights Benefits of Subcutaneous Amivantamab with Lazertinib

More Posts Featuring Mahadi Baig.